Skip to main content
RI

Ruten Inc

Paradromics is developing a high-data-rate brain-computer interface (BCI) designed to restore communication and motor function for patients with severe neurological conditions. Their invasive device aims to translate neural signals into control commands for external devices, offering new reconstructive treatment options where standard therapies are insufficient.

Sacramento, United StatesFounded 20237300+ followers
Updated 3 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Product

Problem

Patients with severe neurological conditions often lack effective means to communicate or control motor functions, especially when standard therapies are insufficient. Existing brain-computer interface (BCI) technologies may not provide the data throughput and signal fidelity needed for complex reconstructive treatments.

Solution

Ruten is developing a high-data-rate, invasive brain-machine interface (BMI) designed to restore communication and motor function in patients with severe neurological conditions. The device aims to translate neural signals into control commands for external devices, offering new reconstructive treatment options. By establishing a direct communication pathway between the brain and external technology, Ruten seeks to provide a means for patients to regain lost abilities and improve their overall well-being. The company focuses on developing solutions for cases where standard options are either infeasible or ineffective.

Target Audience

The primary target audience includes patients with severe neurological conditions who have limited or no effective treatment options available.

Features

  • High-data-rate brain-computer interface for real-time neural signal processing.
  • Invasive device designed for direct implantation and long-term use.
  • Neural signal translation into control commands for external devices.
  • Focus on restoring communication and motor function.
This profile is AI-generated and may contain inaccuracies.